Comparaison des anti-CD20 et du natalizumab chez des patients avec une SEP très active
Fabien Rollot
,
Couturier Justine
,
Romain Casey
,
Emmanuelle Leray
,
Sandra Vukusic
et al.
Journal articles
hal-03820845v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
David-Axel Laplaud
,
Romain Casey
,
Laetitia Barbin
,
Marc Debouverie
,
Jerome de Sèze
et al.
Journal articles
inserm-02289153v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France
Sandra Vukusic
,
Fabien Rollot
,
Romain Casey
,
Julie Pique
,
Romain Marignier
et al.
Journal articles
hal-02302155v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis
F. Rollot
,
Romain Casey
,
Marc Debouverie
,
Gilles Edan
,
S. Wiertlewski
et al.
Multiple Sclerosis Journal , 2018, 24, pp.344-345
Journal articles
hal-01935071v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Determinants of Therapeutic Lag in Multiple Sclerosis
Izanne Roos
,
Emmanuelle Leray
,
Federico Frascoli
,
Romain Casey
,
Dana Horakova
et al.
Neurology , 2020, 94 (15)
Journal articles
hal-02929410v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
Camille Sabathé
,
Romain Casey
,
Sandra Vukusic
,
Emmanuelle Leray
,
Guillaume Mathey
et al.
Journal articles
hal-04086418v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments
Mathilde Lefort
,
Sandra Vukusic
,
Romain Casey
,
Gilles Edan
,
Emmanuelle Leray
et al.
Journal articles
hal-03690316v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
Laetitia Barbin
,
Chloé Rousseau
,
Natacha Jousset
,
Romain Casey
,
Marc Debouverie
et al.
Journal articles
hal-01299977v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal
Fabien Rollot
,
Justine Couturier
,
Romain Casey
,
Sandrine Wiertlewski
,
Marc Debouverie
et al.
Journal articles
hal-03594074v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset
Olivier Commowick
,
Michaël Kain
,
Romain Casey
,
Roxana Ameli
,
Jean-Christophe Ferré
et al.
Journal articles
hal-03358961v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Izanne Roos
,
Emmanuelle Leray
,
Romain Casey
,
Dana Horakova
,
Eva Havrdova
et al.
Journal articles
hal-03282036v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
Antoine Gavoille
,
Fabien Rollot
,
Romain Casey
,
Marc Debouverie
,
Emmanuelle Le Page
et al.
Journal articles
hal-03963580v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Izanne Roos
,
Charles Malpas
,
Emmanuelle Leray
,
Romain Casey
,
Dana Horakova
et al.
Journal articles
hal-03776286v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study
D. A. Laplaud
,
L. Barbin
,
Chloé Rousseau
,
N. Jousset
,
Romain Casey
et al.
Multiple Sclerosis Journal , 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.62--63
Journal articles
hal-01259392v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Determinants of Therapeutic Lag in Multiple Sclerosis
Izanne Roos
,
Emmanuelle Leray
,
Federico Frascoli
,
Romain Casey
,
J William L Brown
et al.
Journal articles
hal-03223056v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disease-modifying therapies use in primary progressive multiple sclerosis patients in France data from the OFSEP cohort over the 1996-2017 period
Emmanuelle Leray
,
F. Rollot
,
Romain Casey
,
J. de Seze
,
D. A. Laplaud
et al.
Journal articles
hal-01716028v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Identification of Therapeutic Lag in Multiple Sclerosis
Izanne Roos
,
Emmanuelle Leray
,
Federico Frascoli
,
Romain Casey
,
Dana Horakova
et al.
Neurology , 2020, 94 (15)
Journal articles
hal-02929403v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Cumulative effects of therapies on disability in relapsing multiple sclerosis
Fabien Rollot
,
Romain Casey
,
Emmanuelle Leray
,
Marc Debouverie
,
Gilles Edan
et al.
Journal articles
hal-03128421v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag
I. Roos
,
Emmanuelle Leray
,
Romain Casey
,
D. Horakova
,
E. Kubala Havrdova
et al.
Multiple Sclerosis Journal , 2020, 26 (3_SUPPL), pp.534-535
Journal articles
hal-03127244v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Predictive medicine in multiple sclerosis: A systematic review
Julie Havas
,
Emmanuelle Leray
,
Fabien Rollot
,
Romain Casey
,
Laure Michel
et al.
Journal articles
hal-02470973v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis
Audrey Gauthier
,
Sébastien Viel
,
Magali Perret
,
Guillaume Brocard
,
Romain Casey
et al.
Journal articles
hal-03216866v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Emulation d’essai clinique randomisé chez des patients atteints d’une sclérose en plaques pour estimer le bénéfice d’un changement de traitement précoce vers un traitement de seconde ligne : approche par scores de propensions dépendant du temps
Camille Sabathé
,
Romain Casey
,
Sandra Vukusic
,
Emmanuelle Leray
,
David-Axel Laplaud
et al.
Journal articles
hal-03820873v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies
Johanna Andersen
,
Sifat Sharmin
,
Mathilde Lefort
,
Nils Koch-Henriksen
,
Finn Sellebjerg
et al.
Journal articles
hal-03268539v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017
Emmanuelle Leray
,
F. Rollot
,
Romain Casey
,
J. de Seze
,
D. A. Laplaud
et al.
Journal articles
hal-01716027v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990–2017 ? Étude des données de l’Observatoire français de la SEP
Emmanuelle Leray
,
Jonathan Roux
,
F. Rollot
,
Romain Casey
,
J. de Seze
et al.
Journal articles
hal-02921604v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics
Romain Casey
,
I. El-Bahi
,
F. Rollot
,
Francis Guillemin
,
D. -A. Laplaud
et al.
Journal articles
hal-02363488v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Izanne Roos
,
Emmanuelle Leray
,
Federico Frascoli
,
Romain Casey
,
J William L Brown
et al.
Journal articles
hal-02955197v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions
Stephane Kremer
,
Salem Hannoun
,
Fabrice Bonneville
,
Francoise Durand-Dubief
,
Thomas Tourdias
et al.
Journal articles
hal-02570313v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Quelle utilisation des traitements de fond chez des patients ayant une SEP rémittente en France sur la période 1990–2017 ? Éléments de réponse à partir des données de l’Ofsep
Emmanuelle Leray
,
Fabien Rollot
,
Romain Casey
,
Jonathan Roux
,
Jérôme de Seze
et al.
Journal articles
hal-02921615v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sifat Sharmin
,
Mathilde Lefort
,
Johanna Balslev Andersen
,
Emmanuelle Leray
,
Dana Horakova
et al.
Journal articles
hal-03367246v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More